Tesamorelin
- Generic Name
- Tesamorelin
- Brand Names
- Egrifta
- Drug Type
- Biotech
- CAS Number
- 218949-48-5
- Unique Ingredient Identifier
- MQG94M5EEO
Overview
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Background
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Indication
Tesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Associated Conditions
- Lipodystrophies
Research Report
Tesamorelin: A Comprehensive Review of its Pharmacology, Efficacy, and Safety in HIV-Associated Lipodystrophy
1. Introduction to Tesamorelin
Overview
Tesamorelin is a synthetic peptide analogue of the endogenous hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH), also known as Growth Hormone Releasing Factor (GRF).[1] It is classified pharmacologically as a GHRH analog and a somatotropin agonist.[1]
Chemical Structure and Modification
Tesamorelin is a polypeptide comprising the full 44 amino acid sequence of human GHRH.[2] Its structure is distinguished by a modification at the N-terminus, where a trans-3-hexenoic acid group is attached.[4] This chemical modification serves a crucial function: it enhances the peptide's stability and confers resistance to enzymatic degradation, particularly cleavage by dipeptidyl aminopeptidase (DPP-IV), compared to the native GHRH molecule.[2] This increased stability results in an improved pharmacokinetic profile, allowing for therapeutic efficacy with subcutaneous administration.[2] The Chemical Abstracts Service (CAS) Registry Number for Tesamorelin is 218949-48-5.[5] Its molecular formula is C221H366N72O67S, corresponding to a molecular weight of approximately 5135.8 g/mol.[5]
Primary Indication
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.